Kathee Littrell

Kathee Littrell is an experienced Investor Relations professional with a career spanning over two decades in various leadership roles. Currently serving as an Investor Relations Consultant at Surrozen since April 2021, Kathee previously held the position of Vice President of Investor Relations at Jazz Pharmaceuticals from January 2013 to March 2021, leading the global investor relations function. Prior to this, Kathee worked as a Consultant for Investor Relations Communications at RCI Communications in 2012, focusing on strategic communications and executive preparation for investor meetings. Kathee also provided consulting services in Investor Relations from 2010 to 2012, specializing in strategic communication planning for biotech investor engagements. Kathee's extensive background includes serving as Vice President of Investor Relations at Genentech from 1992 to 2010, with responsibilities in commercial, clinical post-marketing studies, and investor communications. Academic qualifications include a Ph.D. in Nursing and a Master of Science in Nursing, both obtained from the University of Miami School of Nursing.